PL2780022T3 - Preparaty farmaceutyczne ludzkich komórek rpe i ich zastosowania - Google Patents

Preparaty farmaceutyczne ludzkich komórek rpe i ich zastosowania

Info

Publication number: PL2780022T3
Authority: PL; Poland
Prior art keywords: pharmaceutical preparations; rpe cells; human rpe; human; cells
Prior art date: 2011-11-14

Application number

PL12848968T

Other languages

English (en)

Inventor

Roger Gay

Irina Klimanskaya

Robert Lanza

Original Assignee

Astellas Inst For Regenerative Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-14

Filing date

2012-11-14

Publication date

2019-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47470610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2780022(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-14 Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine

2019-11-29 Publication of PL2780022T3 publication Critical patent/PL2780022T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Cell Biology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Developmental Biology & Embryology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Diabetes (AREA)
Immunology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Mechanical Engineering (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)

PL12848968T 2011-11-14 2012-11-14 Preparaty farmaceutyczne ludzkich komórek rpe i ich zastosowania PL2780022T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201161559521P	2011-11-14	2011-11-14
US201261589741P	2012-01-23	2012-01-23
US201261724047P	2012-11-08	2012-11-08
PCT/US2012/065091 WO2013074681A1 (en)	2011-11-14	2012-11-14	Pharmaceutical preparations of human rpe cells and uses thereof
EP12848968.9A EP2780022B2 (en)	2011-11-14	2012-11-14	Pharmaceutical preparations of human rpe cells and uses thereof

Publications (1)

Publication Number	Publication Date
PL2780022T3 true PL2780022T3 (pl)	2019-11-29

Family

ID=47470610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12848968T PL2780022T3 (pl)	2011-11-14	2012-11-14	Preparaty farmaceutyczne ludzkich komórek rpe i ich zastosowania

Country Status (23)

Country	Link
US (3)	US20130195806A1 (pl)
EP (2)	EP3563860A1 (pl)
JP (6)	JP6506023B2 (pl)
KR (1)	KR102054904B1 (pl)
CN (2)	CN113786417A (pl)
AU (5)	AU2012340020A1 (pl)
CA (2)	CA3178098A1 (pl)
CY (1)	CY1121819T1 (pl)
DK (1)	DK2780022T4 (pl)
ES (1)	ES2734453T3 (pl)
FI (1)	FI2780022T4 (pl)
GB (1)	GB2496969A (pl)
HK (1)	HK1202456A1 (pl)
HR (1)	HRP20191110T1 (pl)
HU (1)	HUE044778T2 (pl)
IL (4)	IL308205A (pl)
LT (1)	LT2780022T (pl)
PL (1)	PL2780022T3 (pl)
PT (1)	PT2780022T (pl)
RS (1)	RS59050B1 (pl)
SI (1)	SI2780022T1 (pl)
TW (5)	TWI655286B (pl)
WO (1)	WO2013074681A1 (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005070011A2 (en) *	2004-01-23	2005-08-04	Advanced Cell Technology, Inc.	Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en)	2004-01-23	2010-09-14	Advanced Cell Technology, Inc.	Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
AU2008312007A1 (en)	2007-10-12	2009-04-23	Advanced Cell Technology, Inc.	Improved methods of producing RPE cells and compositions of RPE cells
IL281453B (en)	2009-11-17	2022-07-01	Astellas Inst For Regenerative Medicine	Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
US10852069B2 (en)	2010-05-04	2020-12-01	Fractal Heatsink Technologies, LLC	System and method for maintaining efficiency of a fractal heat sink
CA2806127C (en)	2010-07-23	2021-12-21	Advanced Cell Technology, Inc.	Methods for detection of rare subpopulations of cells and highly purified compositions of cells
ES2574956T3 (es)	2011-09-26	2016-06-23	Preanalytix Gmbh	Estabilización y aislamiento de ácidos nucleicos extracelulares
US11021733B2 (en)	2011-09-26	2021-06-01	Qiagen Gmbh	Stabilization and isolation of extracellular nucleic acids
EP2761020B1 (en)	2011-09-26	2018-06-13	Qiagen GmbH	Stabilisation and isolation of extracellular nucleic acids
CN113786417A (zh) *	2011-11-14	2021-12-14	安斯泰来再生医药协会	人rpe细胞的药物制剂及其用途
JP6608280B2 (ja)	2012-09-25	2019-11-20	キアゲンゲーエムベーハー	生物学的試料の安定化
US20150368713A1 (en)	2013-02-01	2015-12-24	THE UNITED STATES OF AMERICAN, as represented by the Secretary, Department of Health and Human Serv	METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
CN105121643A (zh)	2013-03-18	2015-12-02	凯杰有限公司	细胞外核酸的稳定化和分离
WO2014146781A1 (en)	2013-03-18	2014-09-25	Qiagen Gmbh	Stabilisation of biological samples
US11624053B2 (en)	2013-11-27	2023-04-11	Kyoto Prefectural Public University Corporation	Application of laminin to corneal endothelial cell culture
CA2933083A1 (en)	2013-12-11	2015-06-18	Pfizer Limited	Method for producing retinal pigment epithelial cells
CN106102766A (zh) *	2014-01-22	2016-11-09	皮埃尔与玛丽·居里大学 - 巴黎第六大学	用于治疗视网膜炎症的试剂
EP2898896A1 (en) *	2014-01-22	2015-07-29	Université Pierre et Marie Curie (Paris 6)	Agents for use in the treatment of retinal inflammation
CA2940692A1 (en) *	2014-03-18	2015-09-24	Qiagen Gmbh	Stabilization and isolation of extracellular nucleic acids
WO2015175504A1 (en) *	2014-05-12	2015-11-19	The Johns Hopkins University	Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
WO2015175783A1 (en) *	2014-05-15	2015-11-19	International Stem Cell Corporation	Chemical differentiation of pluripotentstem cells into retinal epithelial cells
US10597633B2 (en)	2014-05-16	2020-03-24	Koninklijke Nederlandse Akademie Van Wetenschappen	Culture method for organoids
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
US20160095307A1 (en)	2014-10-07	2016-04-07	NuTech Medical, Inc.	Method and composition for hypothermic storage of placental tissue
KR20210013299A (ko)	2014-10-17	2021-02-03	코디악 사이언시스 인코포레이티드	부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CN107073067A (zh) *	2014-10-31	2017-08-18	京都府公立大学法人	使用层粘连蛋白的新的角膜的治疗
US11918630B2 (en) *	2014-10-31	2024-03-05	Kyoto Prefectural Public University Corporation	Treatment of retina and nerve using laminin
US11865189B2 (en)	2014-12-18	2024-01-09	Sorbonne Universite	Transgenic RPE cells overexpressing OTX2 for the treatment of retinal degeneration
JP2018501281A (ja) *	2014-12-30	2018-01-18	セルキュアニューロサイエンシズリミテッド	網膜疾患を治療する方法
ES2774456T3 (es)	2014-12-30	2020-07-21	Cell Cure Neurosciences Ltd	Poblaciones de células del RPE y métodos de generación de las mismas
ES2880346T3 (es)	2014-12-30	2021-11-24	Cell Cure Neurosciences Ltd	Evaluación de poblaciones de células epiteliales de pigmento retiniano
CA2980580C (en) *	2015-03-23	2024-01-23	Astellas Institute For Regenerative Medicine	Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN105013010B (zh) *	2015-07-07	2018-01-12	中山大学中山眼科中心	一种辅助iPS‑RPE移植的层粘连蛋白膜
PL3331994T3 (pl)	2015-08-05	2023-01-30	Cell Cure Neurosciences Ltd.	Wytwarzanie komórek nabłonka barwnikowego siatkówki
BR112018003031B1 (pt)	2015-08-18	2023-12-26	Astellas Institute For Regenerative Medicine	Solução salina de vida útil prolongada, preparação celular, seus usos, método de obtenção e armazenamento de preparação celular, composição farmacêutica e kit
JP6986016B2 (ja) *	2015-09-08	2021-12-22	フジフィルムセルラーダイナミクス，インコーポレイテッド	Ｍａｃｓを用いた幹細胞由来網膜色素上皮の精製
EP3377645B1 (en)	2015-11-20	2023-10-04	Qiagen GmbH	Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
IL260323B2 (en)	2015-12-30	2025-01-01	Kodiak Sciences Inc	Antibodies and their conjugates
GB201603569D0 (en)	2016-03-01	2016-04-13	Koninklijke Nederlandse Akademie Van Wetenschappen	Improved differentiation method
CN106420809B (zh) *	2016-08-31	2017-08-08	浙江济民制药股份有限公司	一种眼科手术灌注液
US12215349B2 (en) *	2016-12-13	2025-02-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
US11076984B2 (en) *	2017-03-13	2021-08-03	Gyroscope Therapeutics Limited	Method of performing subretinal drainage and agent delivery
CN118021843A (zh) *	2017-03-16	2024-05-14	谱系细胞疗法公司	用于测量视网膜疾病疗法的疗效的方法
CN110662549A (zh) *	2017-05-01	2020-01-07	路易斯安娜州立大学监测委员会，农业和机械学院	用于治疗眼病的组合物和方法
US20210000102A1 (en) *	2017-12-29	2021-01-07	Cell Cure Neurosciences Ltd.	Retinal pigment epithelium cell compositions
US12029683B2 (en)	2018-02-22	2024-07-09	Alcon Inc.	Ocular implant and delivery system
KR20200140817A (ko) *	2018-03-02	2020-12-16	코디악 사이언시스 인코포레이티드	Il-6 항체 그리고 이의 융합 작제물 및 접합체
JP7604370B2 (ja) *	2018-11-19	2024-12-23	ザユナイテッドステイツオブアメリカアズリプリゼンテッドバイザセクレタリー、デパートメントオブヘルスアンドヒューマンサービシーズ	生分解性組織置換インプラントおよびその使用
CN113874494A (zh) *	2019-05-28	2021-12-31	豪夫迈·罗氏有限公司	产生单核细胞祖细胞的方法
KR102198942B1 (ko) *	2019-07-02	2021-01-05	의료법인 성광의료재단	Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
EP4013297A4 (en)	2019-08-16	2023-12-13	Poltorak Technologies, LLC	DEVICE AND METHOD FOR MEDICAL DIAGNOSIS
CN114786731A (zh)	2019-10-10	2022-07-22	科达制药股份有限公司	治疗眼部病症的方法
IL292610A (en)	2019-10-30	2022-07-01	Astellas Inst For Regenerative Medicine	Methods for producing retinal pigment epithelium cells
CA3161672A1 (en) *	2019-11-22	2021-05-27	Sigilon Therapeutics, Inc.	Monoclonal cell lines expressing an exogenous substance and uses thereof
TW202216158A (zh) *	2020-07-10	2022-05-01	國立研究開發法人理化學研究所	網膜色素上皮細胞之移植用存活促進劑
CN112544612A (zh) *	2020-12-18	2021-03-26	江苏艾尔康生物医药科技有限公司	冻存液及其在rpe细胞冻存中的应用
CN112834411B (zh) *	2021-01-07	2022-05-27	上海交通大学	应用于质谱流式技术的金属纳米探针及制备方法和应用
CN112926116B (zh) *	2021-03-01	2023-02-17	哈尔滨工业大学	一种基于虚拟现实的体育馆火灾疏散行为数据收集系统及其收集方法
CN114246938A (zh) *	2022-01-25	2022-03-29	中山大学中山眼科中心	Il-4在制备用于治疗视网膜变性疾病药物中的应用
WO2023149420A1 (ja) *	2022-02-01	2023-08-10	株式会社坪田ラボ	近視を予防または治療するための方法および組成物
CN114561356B (zh) *	2022-03-09	2022-09-13	北京呈诺医学科技有限公司	影响细胞因子分泌的方法及应用
CN118871141A (zh) *	2022-03-16	2024-10-29	住友制药株式会社	移植用介质
WO2024218311A1 (fr) *	2023-04-21	2024-10-24	Pulsesight Therapeutics	Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
WO2024233368A1 (en) *	2023-05-05	2024-11-14	The Regents Of The University Of California	Retinal pigment epithelium cell therapy
CN117625536B (zh) *	2024-01-26	2024-04-30	中国人民解放军总医院第三医学中心	一种人视网膜色素上皮细胞的纯化、培养方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4138205A (en)	1975-12-15	1979-02-06	Hydro Pulse Corporation	Movable stator walls permitting access to tubing in peristaltic pump
US5610753A (en)	1991-12-12	1997-03-11	Eastman Kodak Company	Optical design of laser scanner to reduce thermal sensitivity
GB9608145D0 (en) *	1996-04-19	1996-06-26	British Tech Group	Wound healing
US20040086494A1 (en) *	1996-10-07	2004-05-06	John Constance Mary	Immune privileged cells for delivery of proteins and peptides
US5998423A (en)	1996-10-08	1999-12-07	Therasys, Inc.	Methods for modulating melanin production
US6440933B1 (en)	1997-09-10	2002-08-27	University Of Florida	Compounds and method for the prevention and treatment of diabetic retinopathy
AU759273B2 (en) *	1998-01-02	2003-04-10	Titan Pharmaceuticals, Inc.	Use of retinal pigment epithelial cells for creation of an immune privilege site
US7410798B2 (en)	2001-01-10	2008-08-12	Geron Corporation	Culture system for rapid expansion of human embryonic stem cells
US6943153B1 (en)	1999-03-15	2005-09-13	The Regents Of The University Of California	Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en)	1999-10-22	2001-12-18	Oculex Pharmaceticals, Inc.	Controlled-release biocompatible ocular drug delivery implant devices and methods
US6576422B1 (en) *	2000-10-17	2003-06-10	Rohm And Haas Company	Method for identifying products employing gene expression
EP1339438B1 (en)	2000-11-29	2005-10-19	Allergan Inc.	Preventing transplant rejection in the eye
EP1381349A4 (en) *	2001-04-27	2004-09-29	Gen Hospital Corp	TYROSINASEBESTIMMUNG
US7319002B2 (en) *	2001-08-08	2008-01-15	The Trustees Of The University Of Pennsylvania	Method for purification of viral vectors having proteins which bind sialic acid
AU2002360424A1 (en)	2001-11-26	2003-06-10	Advanced Cell Technology, Inc.	Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20030217374A1 (en)	2002-01-15	2003-11-20	Advanced Cell Technology	Cloning B and T lymphocytes
US20040091936A1 (en)	2002-05-24	2004-05-13	Michael West	Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7803750B2 (en)	2002-07-29	2010-09-28	Duke University	Method of modulating melanin production
US7794704B2 (en) *	2004-01-23	2010-09-14	Advanced Cell Technology, Inc.	Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
WO2005070011A2 (en) *	2004-01-23	2005-08-04	Advanced Cell Technology, Inc.	Improved modalities for the treatment of degenerative diseases of the retina
US7309487B2 (en) *	2004-02-09	2007-12-18	George Inana	Methods and compositions for detecting and treating retinal diseases
US7893315B2 (en)	2004-11-04	2011-02-22	Advanced Cell Technology, Inc.	Derivation of embryonic stem cells and embryo-derived cells
EP1812554A4 (en)	2004-11-04	2008-10-08	Advanced Cell Tech Inc	DERIVATION OF EMBRYONAL STEM CELLS
CN101563449A (zh) *	2006-09-22	2009-10-21	理化学研究所	干细胞培养基及干细胞培养方法
AU2008312007A1 (en) *	2007-10-12	2009-04-23	Advanced Cell Technology, Inc.	Improved methods of producing RPE cells and compositions of RPE cells
GB0806746D0 (en)	2008-04-14	2008-05-14	Ucl Business Plc	Membrane
JP2011520788A (ja) *	2008-04-18	2011-07-21	アリゾナボードオブリージェンツアボディーコープ．オブザステイトオブアリゾナアクティングフォーアンドオンビハーフオブザユニバーシティオブアリゾナ	加齢黄斑変性症を治療する方法および組成物ならびに加齢黄斑変性症を治療する化合物を識別する方法
IL281453B (en) *	2009-11-17	2022-07-01	Astellas Inst For Regenerative Medicine	Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CA2806127C (en) *	2010-07-23	2021-12-21	Advanced Cell Technology, Inc.	Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US20110052678A1 (en) *	2010-11-05	2011-03-03	Shantha Totada R	Method for treating age related macular degeneration
CA2831609C (en)	2011-03-30	2019-06-11	Cellular Dynamics International, Inc.	Priming of pluripotent stem cells for neural differentiation
EP2702135B1 (en) *	2011-04-29	2019-04-17	University of Southern California	Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
CN113786417A (zh) *	2011-11-14	2021-12-14	安斯泰来再生医药协会	人rpe细胞的药物制剂及其用途
EP3922717A1 (en) *	2014-09-05	2021-12-15	Astellas Institute for Regenerative Medicine	Retinal ganglion cells and progenitors thereof

2012
- 2012-11-14 CN CN202110854081.1A patent/CN113786417A/zh active Pending
- 2012-11-14 HU HUE12848968 patent/HUE044778T2/hu unknown
- 2012-11-14 WO PCT/US2012/065091 patent/WO2013074681A1/en active Application Filing
- 2012-11-14 GB GB1220511.8A patent/GB2496969A/en not_active Withdrawn
- 2012-11-14 KR KR1020147016228A patent/KR102054904B1/ko active Active
- 2012-11-14 CA CA3178098A patent/CA3178098A1/en active Pending
- 2012-11-14 JP JP2014541421A patent/JP6506023B2/ja active Active
- 2012-11-14 AU AU2012340020A patent/AU2012340020A1/en not_active Abandoned
- 2012-11-14 SI SI201231636T patent/SI2780022T1/sl unknown
- 2012-11-14 CN CN201280066325.9A patent/CN104080464A/zh active Pending
- 2012-11-14 US US13/676,999 patent/US20130195806A1/en not_active Abandoned
- 2012-11-14 DK DK12848968.9T patent/DK2780022T4/da active
- 2012-11-14 TW TW101142511A patent/TWI655286B/zh active
- 2012-11-14 PL PL12848968T patent/PL2780022T3/pl unknown
- 2012-11-14 TW TW113103167A patent/TW202434266A/zh unknown
- 2012-11-14 LT LTEP12848968.9T patent/LT2780022T/lt unknown
- 2012-11-14 EP EP19164689.2A patent/EP3563860A1/en active Pending
- 2012-11-14 PT PT12848968T patent/PT2780022T/pt unknown
- 2012-11-14 ES ES12848968T patent/ES2734453T3/es active Active
- 2012-11-14 TW TW107102515A patent/TWI719277B/zh active
- 2012-11-14 IL IL308205A patent/IL308205A/en unknown
- 2012-11-14 FI FIEP12848968.9T patent/FI2780022T4/fi active
- 2012-11-14 IL IL287381A patent/IL287381B2/en unknown
- 2012-11-14 TW TW111133463A patent/TWI842079B/zh active
- 2012-11-14 TW TW109136186A patent/TWI785403B/zh active
- 2012-11-14 RS RS20190890A patent/RS59050B1/sr unknown
- 2012-11-14 EP EP12848968.9A patent/EP2780022B2/en active Active
- 2012-11-14 CA CA2855941A patent/CA2855941A1/en active Pending
2014
- 2014-05-13 IL IL232600A patent/IL232600B/en active IP Right Grant
2015
- 2015-03-31 HK HK15103225.4A patent/HK1202456A1/xx unknown
- 2015-05-15 US US14/713,108 patent/US20150366915A1/en not_active Abandoned
2017
- 2017-09-08 AU AU2017225146A patent/AU2017225146C1/en active Active
- 2017-09-25 JP JP2017183914A patent/JP6563996B2/ja active Active
2019
- 2019-02-20 AU AU2019201201A patent/AU2019201201B2/en active Active
- 2019-05-27 JP JP2019098508A patent/JP6899865B2/ja active Active
- 2019-06-18 HR HRP20191110TT patent/HRP20191110T1/hr unknown
- 2019-07-09 CY CY20191100720T patent/CY1121819T1/el unknown
2020
- 2020-03-05 IL IL273107A patent/IL273107B/en unknown
- 2020-07-13 US US16/927,068 patent/US20200405767A1/en not_active Abandoned
2021
- 2021-03-24 JP JP2021049493A patent/JP7081016B2/ja active Active
- 2021-07-06 AU AU2021204719A patent/AU2021204719B2/en active Active
2022
- 2022-05-25 JP JP2022084915A patent/JP7404441B2/ja active Active
2023
- 2023-12-13 JP JP2023209915A patent/JP2024037864A/ja active Pending
2025
- 2025-02-21 AU AU2025201277A patent/AU2025201277A1/en active Pending

Also Published As

Publication number	Publication date
JP2014533289A (ja)	2014-12-11
JP2021113193A (ja)	2021-08-05
SI2780022T1 (sl)	2019-09-30
TW201828960A (zh)	2018-08-16
IL232600B (en)	2020-03-31
JP2024037864A (ja)	2024-03-19
EP2780022B1 (en)	2019-06-05
IL273107B (en)	2021-12-01
IL287381A (en)	2021-12-01
IL308205A (en)	2024-01-01
AU2019201201B2 (en)	2021-04-08
CA3178098A1 (en)	2013-05-23
AU2017225146C1 (en)	2019-08-22
TWI655286B (zh)	2019-04-01
CY1121819T1 (el)	2020-07-31
US20130195806A1 (en)	2013-08-01
RS59050B1 (sr)	2019-08-30
JP6506023B2 (ja)	2019-04-24
JP2022130370A (ja)	2022-09-06
EP2780022A1 (en)	2014-09-24
AU2025201277A1 (en)	2025-03-13
PT2780022T (pt)	2019-07-16
JP2018048144A (ja)	2018-03-29
FI2780022T4 (fi)	2023-07-06
JP7404441B2 (ja)	2023-12-25
AU2012340020A1 (en)	2014-07-03
EP2780022A4 (en)	2015-08-05
TWI719277B (zh)	2021-02-21
JP2019189614A (ja)	2019-10-31
US20200405767A1 (en)	2020-12-31
AU2021204719A1 (en)	2021-08-05
JP7081016B2 (ja)	2022-06-06
AU2021204719B2 (en)	2024-11-21
CN113786417A (zh)	2021-12-14
US20150366915A1 (en)	2015-12-24
TW202317157A (zh)	2023-05-01
IL287381B1 (en)	2023-12-01
LT2780022T (lt)	2019-07-10
HUE044778T2 (hu)	2019-11-28
DK2780022T4 (da)	2024-09-09
DK2780022T3 (da)	2019-07-15
HK1202456A1 (en)	2015-10-02
TW202434266A (zh)	2024-09-01
KR20140096368A (ko)	2014-08-05
WO2013074681A1 (en)	2013-05-23
GB2496969A (en)	2013-05-29
CA2855941A1 (en)	2013-05-23
HRP20191110T1 (hr)	2019-09-20
TWI785403B (zh)	2022-12-01
TWI842079B (zh)	2024-05-11
JP6899865B2 (ja)	2021-07-07
KR102054904B1 (ko)	2019-12-11
AU2017225146A1 (en)	2017-10-05
WO2013074681A9 (en)	2013-11-28
ES2734453T3 (es)	2019-12-10
CN104080464A (zh)	2014-10-01
GB201220511D0 (en)	2012-12-26
EP2780022B2 (en)	2022-09-07
IL232600A0 (en)	2014-06-30
IL273107A (en)	2020-04-30
IL287381B2 (en)	2024-04-01
AU2017225146B2 (en)	2019-01-17
EP3563860A1 (en)	2019-11-06
TW201333200A (zh)	2013-08-16
AU2019201201A1 (en)	2019-03-14
JP6563996B2 (ja)	2019-08-21
TW202120107A (zh)	2021-06-01

Publication	Publication Date	Title
IL287381A (en)	2021-12-01	Pharmaceutical preparations of human rpe cells and their use
IL294095A (en)	2022-08-01	Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
HK1255336A1 (zh)	2019-08-16	藥物製劑及其製備方法
HK1252481A1 (zh)	2019-05-24	疏水性治療劑的製劑、其製備方法及應用
IL231536A (en)	2016-09-29	Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
EP2721019A4 (en)	2014-11-19	THERAPEUTIC ACTIVE COMPOSITIONS AND METHOD FOR THEIR USE
HK1199401A1 (en)	2015-07-03	Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
GB201302653D0 (en)	2013-04-03	Pharmaceutical compositions and methods of treatment
ZA201307641B (en)	2015-04-29	Human tissue factor antibody and uses thereof
EP3628326C0 (en)	2024-02-28	METHODS AND MATERIALS FOR THE TREATMENT OF POMPE DISEASE
HK1187345A1 (en)	2014-04-04	Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
PL2814463T3 (pl)	2016-11-30	Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania
EP2655410A4 (en)	2014-05-07	ANTI-INFLAMMATORY PROTEINS AND METHODS OF PREPARATION AND USE THEREOF
GB201222455D0 (en)	2013-01-30	Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
ZA201402820B (en)	2015-11-25	Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
ZA201402452B (en)	2015-09-30	Novel pyrimethanil formulations and uses thereof in the treatment of crops
SG11201401038VA (en)	2014-07-30	Isolating and therapeutic use of perivascular medicinal cells
EP2785335B8 (en)	2017-08-02	Methods and pharmaceutical compositions for the treatment of darier disease
EP2701689A4 (en)	2014-10-29	PHARMACEUTICAL COMPOSITIONS OF RALTEEGRAVIR, METHODS OF PREPARATION AND USE THEREOF
SG11201406771PA (en)	2014-11-27	Stem cell preparations and methods of use
HK1203147A1 (en)	2015-10-23	Cosmetic and pharmaceutical uses of saccharides
ZA201404052B (en)	2016-05-25	18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17b-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in treatment of endometriosis
GB201112578D0 (en)	2011-08-31	Pharmaceutical preparation and use
PL390701A1 (pl)	2011-09-26	Naturalny preparat farmaceutyczno-kosmetyczny
GB201112739D0 (en)	2011-09-07	Production and administration of therapeutic agents